Primaquine
- Generic Name
- Primaquine
- Drug Type
- Small Molecule
- Chemical Formula
- C15H21N3O
- CAS Number
- 90-34-6
- Unique Ingredient Identifier
- MVR3634GX1
- Background
An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
- Indication
For the treatment of malaria.
- Associated Conditions
- Malaria, Malaria caused by Plasmodium ovale, Malaria caused by plasmodium vivax, Pneumocystis Jirovecii Pneumonia
Malaria Challenge in Healthy Volunteers
- Conditions
- Malaria
- Interventions
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2012-12-13
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT01500980
- Locations
- 🇺🇸
Seattle Biomedical Research Institute's Malaria Clinical Trials Center, Seattle, Washington, United States
Dihydroartemisinin-piperaquine and Primaquine for Uncomplicated Plasmodium Falciparum Cases
- Conditions
- Malaria
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 374
- Registration Number
- NCT01392014
- Locations
- 🇮🇩
Hanura Primary Health Center, Lampung, Sumatra, Indonesia
Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra
- Conditions
- Malaria
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2012-03-23
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 77
- Registration Number
- NCT01389557
- Locations
- 🇮🇩
Inge Sutanto, Hanura Primary Health Center, Lampung, Sumatra, Indonesia
Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse
- Conditions
- Malaria, Vivax
- Interventions
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 851
- Registration Number
- NCT01376167
- Locations
- 🇹🇭
GSK Investigational Site, Tak, Thailand
Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 468
- Registration Number
- NCT01365598
- Locations
- 🇺🇬
Walukuba Health Centre IV, Jinja, Eastern Region, Uganda
Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria
- Conditions
- Vivax Malaria
- Interventions
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2013-08-29
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 331
- Registration Number
- NCT01288820
- Locations
- 🇮🇩
Labuhan Batu Utara Regency Tanjung leidong village, North Sumatra, North Sumatera, Indonesia
G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 192
- Registration Number
- NCT01205178
- Locations
- 🇹🇭
GSK Investigational Site, Tak, Thailand
Incidence of Vivax Along the Thai Burma Border
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 403
- Registration Number
- NCT01076868
- Locations
- 🇹🇭
Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand
Trial of Artesunate Combination Therapy in Pakistan
- Conditions
- Uncomplicated Falciparum Malaria
- Interventions
- Drug: sulphadoxine-pyrimethamine (SP)
- First Posted Date
- 2009-08-14
- Last Posted Date
- 2009-08-14
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 588
- Registration Number
- NCT00959517
- Locations
- 🇵🇰
HealthNet International, Peshawar, Pakistan
Randomized Trial of Two Antimalarial Treatments for Clearing Low Density P.Falciparum Parasitaemia in Sudan
- Conditions
- Plasmodium Infections
- Interventions
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2007-10-31
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 104
- Registration Number
- NCT00330902
- Locations
- 🇸🇩
Tropical Medicine Research Institute, Khartoum, Sudan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.